Contraception. What is new?

Archil Khomasuridze, Ludmila Barbakadze


Introduction: In this review, we discuss three main points: 1. What are the main achievements of modern contraception? 2. What could be done better?  3. Contraception in the future.

In I part we present all the new achievements in contraception including WHO data. It is essential, that, family planning/contraception reduces the rate of artificial abortion, especially unsafe abortion. Meantime we are aware; that the ideal contraceptive does not exist yet and the activities for its creation are going on. We suppose that a lot could be done better.  For instance: it is lack of male contraception, Mifepristone successfully can substitute any type progestogene in female and male hormonal contraceptives. In addition ‘’The Modification of the Method of Hormonal Contraception” (MHC) gives the possibility of an 80% decrease in the frequency of side effects of the combined oral contraceptives and the “Phasic” contraceptives are considered as a huge additional benefit of the hormonal contraception. Contraception in the future should be based on something principally new. It is impossible to say how achievable the goal is, but still, we would like to present some of our promising options of female and male contraceptives for the future such as the fertility chip, origami female condom, dapavirine vaginal ring, vazalgel, gamendazole, clean sheet pill.

Method: The data concerning the issue was collected from the Google, NCBI and PubMed database by the use of keywords, such as: family planning, modern contraception, male contraception, emergency contraception, hormonal contraception, mifepristone, the future of contraception. The years for the search were 1989-2018.

Conclusion: The combat for the ideal contraception is continuing. It is necessary to develop male contraceptives and bring them up to the level of the females. Female contraception requires not only new methods but also, more appropriate use of already existing ones. The mechanism of action of the future contraceptives should be based, not only on biological, but physical and chemical processes as well.


Family planning; Modern contraception; Male contraception; Emergency contraception; Hormonal contraception; Mifepristone; Future of contraception.

Full Text:



Contraception [Internet]. Guttmacher Institute. 2019 [cited 2 March 2019]. Available from:

Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Social science & medicine. 1997 May 1;44(9):1303-12.

Segal SJ. Contraceptive development and better family planning. Bulletin of the New York Academy of Medicine. 1996;73(1):92.

Tran NT, Yameogo WM, Gaffield ME, Langwana F, Kiarie J, Kulimba DM, Kouanda S. Postpartum family-planning barriers and catalysts in Burkina Faso and the Democratic Republic of Congo: a multiperspective study. Open access journal of contraception. 2018;9:63.

Colin Tidy. What is the future of contraception? [Internet]. Patient. 2017 November . Available from:

David Yeo. Carl Djerassi: “We know exactly how to develop the male pill, but there is no single pharmaceutical company that will touch it”. The Independent. 2014 April 20: 21 [Internet]. Available from:

KRUGER, R. J.Book Review of Molecules and Medicine Molecules and Medicine. Edited by E. J. Corey , B. Czako , and L. Kurti ( Harvard University). John Wiley and Sons, Hoboken, NJ. 2007. xii + 234 pp. 7 × 10 in. $50.00. ISBN 978-0-470-227497-7 (paperback).

Maria B, Stampf F. Termination of early pregnancy using mifepristone in combination with prostaglandin analogs. Acta Obstetricia et Gynecologica Scandinavica. 1989;68(S149):31-32.

Von Hertzen H, Piaggio G, Peregoudov A, Ding J, Chen J, Song S, Bártfai G, Ng E, Gemzell-Danielsson K, Oyunbileg A, Wu S. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. The Lancet. 2002 Dec 7;360(9348):1803-10.

Long B, April M. What Interventions Are Most Effective for Emergency Contraception ?. Annals of Emergency Medicine. 2018;72(1):93-95.

Trussell J, Raymond EG, Cleland K. Emergency contraception: A last chance to prevent unintended pregnancy. Contemporary Readings in Law & Social Justice. 2014 Jul 1;6(2).

Khomasuridze A. Modification of hormonal contraception. Gynecological Endocrinology. 1998; 13 (3): 71-3

Haider Z, D'Souza R. Non–contraceptive benefits and risks of contraception. Best Practice & Research Clinical Obstetrics & Gynaecology. 2009 Apr 1;23(2):249-62.

Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case‐control study. BJOG: An International Journal of Obstetrics & Gynaecology. 1999 Aug 1;106(8):857-60.

Schindler AE. Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2004 Feb 10;112(2):136-41.

Nieschlag E. Clinical trials in male hormonal contraception. Contraception. 2010 Nov 1;82(5):457-70.

McLachlan RI. Male hormonal contraception: a safe, acceptable and reversible choice. The Medical Journal of Australia. 2000 Mar 20;172(6):254-5.

Patel DP, Chandrapal JC, Hotaling JM. Hormone-based treatments in subfertile males. Current urology reports. 2016 Aug 1;17(8):56.

Khourdaji I, Zillioux J, Eisenfrats K, Foley D, Smith R. The future of male contraception: a fertile ground. Translational andrology and urology. 2018 May;7(Suppl 2):S220.

Guha SK, inventor; Guha, Sujoy K., assignee. Contraceptive for use by a male. United States patent US 5,488,075. 1996 Jan 30.

Reversible inhibition of sperm under guidance - Infogalactic: the planetary knowledge core [Internet]. 2019 [cited 2 March 2019]. Available from:

Tash JS, Attardi B, Hild SA, Chakrasali R, Jakkaraj SR, Georg GI. A novel potent indazole carboxylic acid derivative blocks spermatogenesis and is contraceptive in rats after a single oral dose. Biology of reproduction. 2008 Jun 1;78(6):1127-38.

The Contraceptive Pipeline Database [Internet]. 2019 [cited 2 March 2019]. Available from:

Olga Kazan. Block that sperm! The future of birth control, from remote-controlled implants to—at long last—a pill for men. The Atlantic. 2015 March.

Mnatsakanyan MM, Queiroz EF, Marcourt L, Prajogo B, Wolfender JL. Chemical profile of Justicia gendarussa a medicinal plant used for male contraception. Planta Medica. 2016 Dec;82(S 01):P229.

Wang Z, Widgren EE, Richardson RT, Orand MG. Eppin: a molecular strategy for male contraception. Society of Reproduction and Fertility supplement. 2007;65:535-42.

Ada GL, Griffin PD. Vaccines for fertility regulation: the assessment of their safety and efficacy: proceedings of a Symposium on Assessing the Safety and Efficacy of Vaccines to Regulate Fertility, Geneva, June 1989.

Gupta SK, Gupta N, Suman P, Choudhury S, Prakash K, Gupta T, Sriraman R, Nagendrakumar SB, Srinivasan VA. Zona pellucida-based contraceptive vaccines for human and animal utility. Journal of reproductive immunology. 2011 Mar 1;88(2):240-6.

Lekhwani S, Vaswani ND, Ghalaut VS, Shanker V, Singh R. Immunocontraceptives: How far from reality?. Advanced biomedical research. 2014;3.

Annual Report 2014 [Internet]. Bill & Melinda Gates Foundation. 2019 [cited 2 March 2019]. Available from:

Fontaine C. Long-term contraception in a small implant: A review of Suprelorin (deslorelin) studies in cats. Journal of Feline Medicine and Surgery. 2015 Sep 17(9):766-71

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2016 Jan 2;387(10013):53-60.

Seidman D, Hemmerling A, Smith-McCune K. Emerging technologies to prevent pregnancy and sexually transmitted infections in women. InSeminars in reproductive medicine 2016 May (Vol. 34, No. 03, pp. 159-167). Thieme Medical Publishers.

Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, Bekker LG, Etima J, Nakyanzi T, Mayo AJ, Katz A. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS (London, England). 2017 May 15;31(8):1159.


  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)